First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized TrialCesare Gridelli, Francesco Perrone, Fortunato Ciardiello et al.|Journal of Clinical Oncology|2012Cited by 234
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung CancerMassimo Di Maïo, Cesare Gridelli, Natasha B. Leighl et al.|Journal of Thoracic Oncology|2012Cited by 26
Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC)Rafal Wierzbicki, Munjid Hasballah Abdulkareem, Tarek Amin et al.|Annals of Oncology|1994Cited by 14
Epidermal Growth Factor Receptor (Egfr) and Abcg2 Polymorphisms and Treatment Outcome in the Randomized Phase III Torch Trial in Advanced Non-Small Cell Lung Cancer (Nsclc) PatientsGeoffrey Liu, Francesco Perrone, Cesare Gridelli et al.|Annals of Oncology|2014Cited by 0